Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 4:05 PM
Ignite Modification Date:
2025-12-24 @ 4:05 PM
NCT ID:
NCT06915766
Eligibility Criteria:
Key Inclusion Criteria:
* Able to provide written informed consent and commit to EAP assessments.
* ≥18 years of age.
* Able to swallow tablets.
* Diagnosed with ASM, SM-AHN, MCL, BMM, ISM, or SSM according to the 2022 WHO Classification for SM
* Not receiving adequate disease control on current therapy(ies).
* Have clinically acceptable laboratory screening results.
Exclusion Criteria:
* Patients who are eligible for and/or enrolled in an on-going bezuclastinib clinical trial.
* Patients who discontinued investigational use of bezuclastinib in previous clinical trials due to toxicity or withdrawal of consent.
* Pregnant or currently breastfeeding.
* Prior or ongoing clinically significant illness or medical or physical condition
Other protocol-defined criteria apply.
Sex:
ALL
Minimum Age:
18 Years
Study:
NCT06915766
Study Brief:
Protocol Section:
NCT06915766